PUBLISHER: The Business Research Company | PRODUCT CODE: 1730856
PUBLISHER: The Business Research Company | PRODUCT CODE: 1730856
Fatty acid oxidation disorders (FAODs) are a group of rare inherited metabolic conditions that disrupt the body's ability to convert fats into energy due to a lack or malfunction of specific enzymes necessary for fatty acid breakdown. As a result, fatty acids accumulate in the body, leading to severe energy shortages, hypoglycemia, muscle weakness, and potential organ damage, especially during times of fasting or illness.
The primary types of fatty acid oxidation disorders are long-chain and short-chain disorders. Long-chain fatty acid oxidation disorders (LC-FAODs) are conditions where the body cannot properly metabolize long-chain fatty acids for energy, causing energy deficiencies and metabolic disturbances. Treatment options include medications such as levocarnitine, dextrose, riboflavin, and others, which can be administered through oral or intravenous routes. These medications are distributed through hospital pharmacies, retail pharmacies, drugstores, and online platforms, with end users including hospitals, clinics, and pharmaceutical companies.
The fatty acid oxidation disorders (FAODs) market research report is one of a series of new reports from The Business Research Company that provides fatty acid oxidation disorders (FAODs) market statistics, including the fatty acid oxidation disorders (FAODs) industry global market size, regional shares, competitors with the fatty acid oxidation disorders (FAODs) market share, detailed fatty acid oxidation disorders (FAODs) market segments, market trends, and opportunities, and any further data you may need to thrive in the fatty acid oxidation disorders (FAODs) industry. This fatty acid oxidation disorders (FAODs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The fatty acid oxidation disorders (FAODs) market size has grown strongly in recent years. It will grow from $9.55 billion in 2024 to $10.33 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to factors such as greater awareness, a rise in the prevalence of rare and genetic disorders, an increasing number of product approvals, enhanced government initiatives, and a growing demand for orphan drugs.
The fatty acid oxidation disorders (FAODs) market size is expected to see strong growth in the next few years. It will grow to $13.99 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to the growing demand for sustainable bio-products, the increasing adoption of personalized medicine, earlier diagnosis of FAODs, rising funding for research and development, and a stronger focus on enhancing long-term outcomes. Key trends in the forecast period include the integration of telehealth services, the use of artificial intelligence in diagnostics and drug discovery, advancements in genetic testing, technological innovations, and a shift towards patient-centric care models.
The growing demand for gene therapy is anticipated to drive the expansion of the fatty acid oxidation disorders (FAODs) market in the future. Gene therapy involves modifying or replacing defective genes to treat or prevent diseases. The rising demand for gene therapy is due to its potential to treat genetic disorders, cancer, and rare diseases by targeting the underlying genetic causes. This has led to significant investments and advancements in biotechnology. Gene therapy aims to address metabolic deficiencies caused by fatty acid oxidation disorders by delivering functional genes to restore enzymatic activity, enhance energy production, and prevent disease complications. For example, in April 2024, the American Society of Gene & Cell Therapy reported a 10% increase in the number of gene therapies in Phase III clinical trials in the fourth quarter, marking the first quarterly growth of this kind since the third quarter of 2022. As a result, the rising demand for gene therapy is fueling the growth of the FAODs market.
Companies in the FAODs market are developing innovative solutions such as peroxisome proliferator-activated receptor delta (PPARδ) agonists to improve metabolic control and treatment outcomes for patients with FAODs. A PPARδ agonist activates the PPARδ receptor, which plays a key role in regulating lipid metabolism, inflammation, and energy balance. This approach may offer therapeutic benefits for metabolic disorders and cardiovascular diseases. For instance, in January 2023, Reneo Pharmaceuticals Inc. received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, Mavodelpar (REN001), which targets long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype linked to long-chain fatty acid oxidation disorder (LC-FAOD). By activating PPARδ, Mavodelpar aims to improve mitochondrial function, enhance energy metabolism, and alleviate symptoms related to LC-FAOD.
In October 2024, OnKure Therapeutics Inc., a US-based pharmaceutical company, merged with Reneo Pharmaceuticals Inc. in an undisclosed deal. The merger combines OnKure's expertise in precision oncology with Reneo's resources to accelerate the development of targeted therapies for oncogenic PI3Ka mutations, specifically using mutant-selective PI3Ka inhibitors. Reneo Pharmaceuticals specializes in developing treatments for fatty acid oxidation disorders.
Major players in the fatty acid oxidation disorders (FAODs) market are BASF SE, Thermo Fisher Scientific Inc, Takeda Pharmaceutical Company Limited, Baxter International Inc, Koninklijke DSM NV, Ingredion Incorporated, Lonza Group Ltd, Roquette Freres SA, Dr Reddy's Laboratories Limited, Tate & Lyle PLC, ANI Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Gulshan Polyols Limited, Hubei Guangji Pharmaceutical Co Ltd, Omega Laboratories Limited, Actiza Pharmaceutical Private Limited, Allmpus Laboratories Private Limited, Reneo Pharmaceuticals Inc, Greenwell Lifesciences, and NB Group Co Ltd.
Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2024. The regions covered in fatty acid oxidation disorders (FAODs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the fatty acid oxidation disorders (FAODs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The fatty acid oxidation disorders (FAODs) market consists of revenues earned by entities by providing services such as newborn screening and genetic testing, nutritional therapy, remote monitoring, and patient support. The market value includes the value of related goods sold by the service provider or included within the service offering. The fatty acid oxidation disorders (FAODs) market also includes sales of medical foods and supplements, diagnostic and genetic testing kits, and nutritional supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Fatty Acid Oxidation Disorders (FAODs) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on fatty acid oxidation disorders (faods) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for fatty acid oxidation disorders (faods) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fatty acid oxidation disorders (faods) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.